Strategic Fit Blue Sky BioServices is a midsized biotechnology CRO with capabilities in gene synthesis, plasmids, antibody cloning, recombinant protein production, purification, and screening assays across multiple formats, presenting a broad outsourcing opportunity for biotech and pharma clients seeking end-to-end R&D support.

Acquisition History Blue Sky merged with LakePharma in early 2016, later appearing in press as part of LakePharma. This indicates integration into a larger CDMO network, suggesting expanded capacity, cross-sell potential for existing LakePharma customers, and a broader service catalog to target.

Revenue Range Annual revenue in the 10 to 25 million USD band signals a solid mid-market CRO with room to scale partnerships, making it an attractive target for tier-two biotech and pharma accounts seeking reliable, cost-competitive project execution.

Service Breadth Capabilities cover gene synthesis, plasmid prep, antibody cloning, multi-cell line protein production, purification, and rapid assays in 96/384-well formats, enabling cross-sell into early-stage biotech startups as well as established companies pursuing scale-up and screening efficiency.

Competitive Positioning Emphasis on experienced scientific teams, advanced process technology, quality, and fast turnaround times position Blue Sky as a value-focused CRO for customers prioritizing reliability and speed, offering a compelling angle for outreach to cost-conscious sponsors and programs requiring expedited timelines.